Clinical Trial Update: A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 study of the Ad26.RSV.preF vaccine for preventing lower respiratory tract disease due to respiratory syncytial virus in adults 60 and older completed, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lower Respiratory Tract Disease
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Viruses, Lower Respiratory Tract Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-02-08